Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DBVT
DBV TECHNOLOGIES S.A.
NASDAQ
$13.54
▼ DOWN 6.04% (-0.87)

KEY STATISTICS

Market Cap$323.90 M
52w High$26.18
52w Low$8.70
Dividend Yield—
Frequency—
P/E-6.18
Volume146.05K
Shares Out.23.92M

COMPANY

LEADERSHIP

Daniel Tassé
CHIEF EXECUTIVE
Daniel Tassé

COMPENSATION 2026

Salary$600,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$62,571
Total$3,357,947

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 22, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
161

PRICE TARGET

Target High$51.00
Target Low$40.00
Target Median$48.00
Target Consensus$46.33

UPCOMING EARNINGS

DateOct 28, 2026
DayWednesday
Rev. Est.$664.00K
OCT
28
WED

SPLIT RECORD

DATETYPERATIO
2024-11-29Reverse1:5
2024-06-07Reverse1:2

PRICE

$13.54 ▼ DOWN 6.04% (−$0.87)
OVERLAYS
$13.50$13.80$14.10$14.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.54

About DBV Technologies S.A.

https://www.dbv-technologies.com ↗

DBV Technologies is a French biopharma company developing epicutaneous immunotherapies like Viaskin Peanut (Phase III) and Viaskin Milk (Phase I/II), along with other allergy and autoimmune treatments.

INDUSTRY

Biotechnology

A PRODUCT DBV TECHNOLOGIES S.A. IS KNOWN FOR

Viaskin Peanut
Viaskin Peanut

Viaskin Peanut is a leading EPIT patch for treating peanut allergies in children, designed to desensitize through skin delivery, and has completed Phase 3 trials.

COMPETITORS

COMPETITOR
NVS COMPARE
REGN COMPARE
SNY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
2
LISTED HERE
2
RANKED BY POSITION SIZE
AI
AIIQ
0.42% · 8.0K
APIE
0.01% · 4.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
91.97%
HOLDERS
94
TOP 12 OF 94 · RANKED BY POSITION SIZE
Bioimpact Capital LLC
5.2M sh · $108.91M
Artisan Partners Limited Partnership
3.3M sh · $63.43M
Vivo Capital, LLC
2.7M sh · $55.73M
Janus Henderson Investors Us LLC
2.5M sh · $88.3M
Siren, L.L.C.
1.9M sh · $38.8M
Baker Bros. Advisors LP
1.5M sh · $14.61M
Octagon Capital Advisors LP
1.0M sh · $10.18M
Adar1 Capital Management, LLC
1.0M sh · $21.16M
Perceptive Advisors LLC
964.4K sh · $20.15M
Patient Square Capital LP
693.5K sh · $14.49M
Yiheng Capital Management, L.P.
656.3K sh · $6.56M
Millennium Management LLC
640.9K sh · $12.29M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Mohideen Pharis
Sale · 464 shares
2026-07-29
★
Lee Philina
— · —
2025-10-30
★
OFFICER: CHIEF MEDICAL OFFICER
Mohideen Pharis
Sale · 534 shares
2026-01-29
★
DIRECTOR
BAKER BROS. ADVISORS LP
Purchase · 25.0M shares
2026-01-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
MARKET OUTPERFORM 1
OVERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM Guggenheim BUY Cantor Fitzgerald OVERWEIGHT HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
LBRX$47.73COMPARE
ANRO$35.13COMPARE
ANNX$4.97COMPARE
ALT$3.11COMPARE
LRMR$4.01COMPARE
LXEO$4.86COMPARE
CLLS$3.40COMPARE
AMRN$13.97COMPARE